stella
beta
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations — Stella
Recruiting
Back to Gliomas Harboring IDH1 and/or IDH2 Mutations trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov